Tina Jackson
Psychiatry · Wartburg, TNNPI 1801015821
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,146, more than ten times the $108 reported in 2019.
Across 140 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$787
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$694
- AbbVie$640
- Otsuka America Pharmaceutical, Inc.$608
- Neurocrine Biosciences, Inc.$272
- E.r. Squibb & Sons, L.L.C.$223
- plus $895 from 17 others
What the payments were for
- Food & beverage$3,75891%
- Education$3609%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $787 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $694 |
| AbbVie(2 entities) | 27 | $640 |
| Otsuka America Pharmaceutical, Inc. | 19 | $608 |
| Neurocrine Biosciences, Inc. | 13 | $272 |
| E.r. Squibb & Sons, L.L.C. | 3 | $223 |
| Phathom Pharmaceuticals, Inc. | 6 | $178 |
| Abbott | 8 | $165 |
| Alkermes, Inc. | 3 | $160 |
| Novo Nordisk | 3 | $55 |
| AstraZeneca | 3 | $51 |
| Exact Sciences | 2 | $39 |
| Shire North American Group Inc | 3 | $37 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Inogen, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $25 |
| Indivior Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| USWM, LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$488
- CAPLYTA$369
- ABILIFY ASIMTUFII$347
- ABILIFY MAINTENA$347
- VRAYLAR$250
- Austedo XR$224
- COBENFY$126
- VOQUEZNA$125
- ARISTADA INITIO$122
How this compares
$4,118 in reported general payments places this provider in the 80th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $299,284 |
| IngrezzaValbenazine Tosylate | 13 | $101,100 |
| Invega SustennaPaliperidone Palmitate | 13 | $41,118 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $17,919 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $2,453 |
| Lurasidone Hcl | 12 | $1,249 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $1,103 |
| Quetiapine Fumarate | 53 | $946 |
| Mirtazapine | 57 | $876 |
| Gabapentin | 66 | $866 |
| Aripiprazole | 20 | $771 |
| Duloxetine Hcl | 24 | $649 |
| Clonazepam | 59 | $445 |
| Trazodone Hcl | 16 | $373 |
| Bupropion XlBupropion Hcl | 14 | $363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $787 | $299,28418 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $272 | $101,10013 claims |
| Johnson & JohnsonInvega Sustenna | $25 | $41,11813 claims |
| Axsome Therapeutics, Inc.Auvelity | $28 | $17,91913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Wartburg
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.